Skip to main content

Table 2 Characteristics of the immigrant patients infected with HIV-1 non-B subtypes (N = 29)

From: Prevalence and resistance mutations of non-B HIV-1 subtypes among immigrants in Southern Spain along the decade 2000-2010

Patient code

Origin

Treatment

Subtype in

PR gene

Protease inhibitor

resistance mutations

Subtype in

RT gene

RT inhibitor

resistance mutations

SE58

EE

HAART

A

M36I, V77I

N.D.

N.D.

SE115

CSA

Naive

B

M36I

C

None

SE71

CSA

HAART

C

M36I

C

V118I

SE73

EE

Naive

F

L10V, K20R, M36I

F

None

SE43

CSA

HAART

F

M36I

B

None

SE99

EE

Naive

F

K20R, M36I

F

None

SE108

CSA

Naive

F

K20R, M36I

F

None

SE37

SSA

Naive

G

K20I, M36I

G

K70R, A98G

SE103

SSA

Naive

G

K20I, M36I

G

None

SE31

SSA

Naive

J

K20I, M36I, V77I

J

None

SE91

SSA

Naive

K

M36I, L63P

G

E138A

SE11

SSA

HAART

CRF02_AG

K20I, M36I, L63P

G

None

SE16

SSA

TI

CRF02_AG

K20I, M36I

G

None

SE113

N.D.

Naive

CRF02_AG

K20I, M36I

G

None

SE66

WE

HAART

CRF02_AG

K20I, M36I

CRF02_AG

None

SE59

NAF

HAART

CRF02_AG

K20I, M36I, L90M

CRF02_AG

None

SE67

SSA

HAART

CRF02_AG

K20I, M36I, L63P

CRF02_AG

None

SE49

SSA

Naive

CRF02_AG

K20I, M36I, L63P

CRF02_AG

None

SE50

SSA

TI

CRF02_AG

K20I, M36I, L63P, V77I

CRF02_AG

None

SE33

SSA

TI

CRF02_AG

L10V, K20I, M36I

CRF02_AG

None

SE36

CSA

HAART

CRF02_AG

K20I, M36I

CRF02_AG

None

SE101

SSA

Naive

CRF02_AG

K20I, M36I

CRF02_AG

None

SE110

EE

Naive

CRF02_AG

K20I, M36I

CRF02_AG

None

SE111

SSA

HAART

CRF02_AG

K20I, M36I

CRF02_AG

90I

SE34

SSA

TI

CRF02_AG

K20I, M36I

CRF01_AE

L100I

SE96

SSA

Naive

CRF02_AG

K20I, M36I

CRF02_AG

None

SE62

EE

Naive

CRF01_AE

M36I

CRF01_AE

None

SE60

EE

HAART

CRF01_AE

M36I

CRF01_AE

K103N

SE19

SSA

HAART

N.D

N.D.

CRF02_AG

None

  1. Protease and RT inhibitor resistance mutations.
  2. CSA, Central-South America; SSA, Sub-Sahara Africa; EE, Eastern Europe; WE, Western Europe; NAF, Northern Africa. HAART, Highly Active Antiretroviral Therapy. TI, treatment interruption. Bold, major resistance. N.D., not determined.